Abstract
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]
BMC Infectious Diseases Open Access 27 November 2023
-
Origin of tuberculosis in the Paleolithic predicts unprecedented population growth and female resistance
Scientific Reports Open Access 08 January 2020
-
Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells
Scientific Reports Open Access 19 March 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
04 August 2015
The spelling of Voahangy Rasolofo's name has been corrected.
References
Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388–404 (2013).
Zumla, A. et al. Tuberculosis treatment and management — an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir. Med. 3, 220–234 (2015).
Wallis, R. S. & Hafner, R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15, 255–263 (2015).
Bento, C. F., Empadinhas, N. & Mendes, V. Autophagy in the fight against tuberculosis. DNA Cell Biol. 34, 228–242 (2015).
Stanley, S. A. et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Supplementary information
Supplementary information S1 (table)
Interventions under investigation as host-directed therapies for tuberculosis (PDF 282 kb)
Rights and permissions
About this article
Cite this article
Zumla, A., Chakaya, J., Hoelscher, M. et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov 14, 511–512 (2015). https://doi.org/10.1038/nrd4696
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4696
This article is cited by
-
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]
BMC Infectious Diseases (2023)
-
Host-directed immunotherapy of viral and bacterial infections: past, present and future
Nature Reviews Immunology (2023)
-
Origin of tuberculosis in the Paleolithic predicts unprecedented population growth and female resistance
Scientific Reports (2020)
-
Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells
Scientific Reports (2019)
-
Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets
BMC Systems Biology (2018)